SEC Form 4 · accession 0001209191-17-051801
FIVE PRIME THERAPEUTICS INC · FPRX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Lewis T Williams
Officer — President, CEO and Chairman · Director
Period of report
Sep 1, 2017
Accepted (ET)
Sep 6, 2017 · 8:00 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001175505
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 1, 2017 | F | 7,827 | $34.34 | D | 381,958 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Includes 600 shares acquired on November 15, 2016 and 431 shares acquired on May 15, 2017 pursuant to Five Prime Therapeutics, Inc.'s 2013 Employee Stock Purchase Plan.